Bio-Techne Corporation
General ticker "TECH" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $9.4B (TTM average)
Bio-Techne Corporation follows the US Stock Market performance with the rate: 29.3%.
Estimated limits based on current volatility of 1.6%: low 62.75$, high 64.73$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2025-08-18, amount 0.08$ (Y0.50%)
- Total employees count: 3100 (+1.6%) as of 2024
- US accounted for 56.7% of revenue in the fiscal year ended 2024-06-30
- Top business risk factors: Economic downturns and volatility, Geopolitical risks, Supply chain disruptions, Labor/talent shortage/retention, Cybersecurity threats
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-06-30 to 2027-06-30
- 2025-06-30 to 2026-06-30 estimated range: [39.21$, 68.04$]
- 2026-06-30 to 2027-06-30 estimated range: [39.18$, 67.30$]
Financial Metrics affecting the TECH estimates:
- Negative: with PPE of 26.3 at the end of fiscal year the price was very high
- Positive: 7.86 < Operating profit margin, % of 8.38
- Negative: negative Industry operating cash flow (median)
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 2.79
- Positive: Investing cash flow per share per price, % of -0.44 > -0.66
- Positive: Interest expense per share per price, % of 0.11 <= 0.79
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
Short-term TECH quotes
Long-term TECH plot with estimates
Financial data
| YTD | 2023-06-30 | 2024-06-30 | 2025-06-30 |
|---|---|---|---|
| Operating Revenue | $1,136.70MM | $1,159.06MM | $1,219.63MM |
| Operating Expenses | $837.76MM | $952.37MM | $1,117.38MM |
| Operating Income | $298.94MM | $206.69MM | $102.25MM |
| Non-Operating Income | $39.72MM | $-21.00MM | $-3.79MM |
| Interest Expense | $11.21MM | $15.74MM | $8.51MM |
| R&D Expense | $92.49MM | $96.66MM | $99.50MM |
| Income(Loss) | $338.66MM | $185.69MM | $98.46MM |
| Taxes | $53.22MM | $17.58MM | $25.06MM |
| Profit(Loss)* | $285.26MM | $168.14MM | $73.40MM |
| Stockholders Equity | $1,966.52MM | $2,068.85MM | $1,918.81MM |
| Inventory | $171.64MM | $179.73MM | $189.45MM |
| Assets | $2,638.69MM | $2,703.87MM | $2,557.87MM |
| Operating Cash Flow | $254.39MM | $298.98MM | $287.56MM |
| Capital expenditure | $38.24MM | $62.88MM | $31.01MM |
| Investing Cash Flow | $-265.65MM | $-203.03MM | $-35.18MM |
| Financing Cash Flow | $22.62MM | $-122.40MM | $-253.91MM |
| Earnings Per Share** | $1.81 | $1.07 | $0.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.